Costs of on‐demand and prophylactic treatment for severe haemophilia in Norway and Sweden
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
Summary. The expected annual cost (in the year 2000 prices) for a 30‐year‐old patient with average individual and treatment characteristics for on‐demand EUR 51 832 (95% CI: 44 324–59 341) and for prophylaxis EUR 146 118 (95% CI: 129 965–162 271), was obtained from panel‐data analysis of an 11‐year retrospective panel of 156 patients with severe haemophilia in Norway and Sweden. Costs included haemophilia‐related treatment costs within the health‐care sector (factor concentrate, doctors’ visits, diagnostic procedures, hospitalisation, invasive procedures, etc.) and cost for haemophilia‐related resource use in other sectors (lost production, use of special equipment, adaptation of workplace and domicile, etc). Although costs of lost production, reconstructive surgery and hospitalisation were higher for on‐demand, they did not balance out the higher costs of factor‐concentrate consumption in prophylaxis. The cut‐off risk of premature death, where on‐demand and prophylaxis would have been equally costly, was 3.7 percentage units higher for on‐demand than for prophylaxis. Such a great risk difference has not been reported elsewhere to our knowledge. Estimated cost‐elasticities indicated that annual costs of prophylaxis would increase by approximately the same proportion as a potential increase in the price of factor concentrate and decrease less than proportionately with a reduction in prescribed dose kg−1. For on‐demand, the annual costs would increase by approximately the same proportion as an increase in the prescribed dose kg−1.
